• 1. Converting ginsenosides from stems and leaves of Panax notoginseng by microwave processing and improving their anticoagulant and anticancer activities
  Yuan Qu,Hui-Ying Liu,Xiao-Xi Guo,Yan Luo,Cheng-Xiao Wang,Jiang-Hua He,Tian-Rui Xu,Ye Yang,Xiu-Ming Cui RSC Adv. 2018 8 40471
• 2. Improving natural products identification through molecular features-oriented precursor ion selection and targeted MS/MS analysis: a case study of Zhi-Ke-Yang-Yin capsule
  Hongping Wang,Qiong Yin,ZiJian Wang,Ping Peng,Chunlan Fan,Run Zhang,Chen Zhao,Zhaozhou Lin RSC Adv. 2022 12 33340
• 3. Ginsenoside CK induces apoptosis of human cervical cancer HeLa cells by regulating autophagy and endoplasmic reticulum stress
  Qi Yin,Hua Chen,Run-Hui Ma,Yuan-Yuan Zhang,Miao-Miao Liu,Kiran Thakur,Jian-Guo Zhang,Zhao-Jun Wei Food Funct. 2021 12 5301

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Prenol lipids Triterpenoids
• Triterpenoids

Introduction to 20(S)-Ginsenoside Rh2 (CAS No. 67400-17-3) and Its Emerging Applications in Modern Medicine

20(S)-Ginsenoside Rh2, a bioactive compound derived from the Panax species, particularly *Panax ginseng*, has garnered significant attention in the field of pharmaceutical research due to its remarkable pharmacological properties. With the CAS number 67400-17-3, this ginsenoside exhibits a unique structural configuration that contributes to its distinct biological activities, making it a subject of extensive study in both preclinical and clinical settings.

The chemical structure of 20(S)-Ginsenoside Rh2 features a complex triterpenoid skeleton, which is characteristic of ginsenosides. This molecular framework is responsible for its interaction with various cellular targets, including receptors and enzymes, thereby modulating multiple signaling pathways. The stereochemistry at the C-20 position, specifically the (S) configuration, is crucial for its biological efficacy and distinguishes it from other ginsenosides such as 20(R)-Ginsenoside Rh2.

In recent years, research on 20(S)-Ginsenoside Rh2 has expanded significantly, particularly in the context of cancer therapy. Studies have demonstrated its potential as an adjuvant therapeutic agent, capable of enhancing the efficacy of conventional treatments while minimizing side effects. The compound’s ability to induce apoptosis in cancer cells, inhibit proliferation, and suppress angiogenesis has been extensively documented in vitro and in vivo models.

One of the most compelling aspects of 20(S)-Ginsenoside Rh2 is its ability to modulate immune responses. Emerging research indicates that it can activate natural killer (NK) cells and T lymphocytes, thereby bolstering the body’s innate immune defenses. This immunomodulatory activity is particularly relevant in the context of oncology, where immune evasion is a common feature of malignant tumors. Furthermore, preclinical studies have suggested that 20(S)-Ginsenoside Rh2 may enhance the sensitivity of cancer cells to chemotherapy and radiation therapy, potentially leading to more effective treatment regimens.

The pharmacokinetic profile of 20(S)-Ginsenoside Rh2 has also been a focus of investigation. Its bioavailability can be influenced by various factors, including formulation and administration route. Recent advancements in drug delivery systems have aimed at improving its absorption and distribution within the body. For instance, nanotechnology-based carriers have been explored to enhance targeted delivery to tumor sites, thereby increasing therapeutic efficacy while reducing systemic toxicity.

Another area of interest is the anti-inflammatory properties of 20(S)-Ginsenoside Rh2. Chronic inflammation is implicated in numerous pathological conditions, including cardiovascular diseases and neurodegenerative disorders. Studies have shown that this ginsenoside can inhibit key pro-inflammatory cytokines such as TNF-α and IL-6, suggesting its potential as a therapeutic agent for inflammatory diseases. Additionally, its ability to modulate microglial activity has raised hopes for its application in neuroprotective strategies.

The role of 20(S)-Ginsenoside Rh2 in metabolic disorders has also been explored. Obesity and type 2 diabetes are global health challenges, and research indicates that this compound can improve insulin sensitivity and reduce lipid accumulation in adipose tissue. By modulating key enzymes involved in glucose metabolism and lipid synthesis, 20(S)-Ginsenoside Rh2 may offer a promising approach to managing metabolic syndrome.

From a synthetic chemistry perspective, the total synthesis or semi-synthesis of 20(S)-Ginsenoside Rh2 remains a challenging yet rewarding endeavor. The complex stereochemistry and multiple chiral centers necessitate sophisticated synthetic strategies. Recent breakthroughs in asymmetric synthesis have enabled more efficient production methods, reducing reliance on plant sources and facilitating large-scale manufacturing.

Ethical considerations are also paramount when discussing the use of natural products like 20(S)-Ginsenoside Rh2. Sustainable harvesting practices and environmentally friendly extraction methods are essential to ensure long-term availability without depleting natural resources. Collaborative efforts between researchers, manufacturers, and policymakers are crucial for balancing therapeutic benefits with ecological preservation.

The future direction of research on 20(S)-Ginsenoside Rh2 appears promising, with ongoing studies focusing on elucidating its mechanisms of action at the molecular level. Advanced techniques such as proteomics and metabolomics are being employed to gain deeper insights into its interactions with biological systems. Additionally, clinical trials are underway to evaluate its safety and efficacy in human populations suffering from various diseases.

In conclusion,20(S)-Ginsenoside Rh2 (CAS No. 67400-17-3) represents a significant advancement in natural product-based medicine. Its multifaceted biological activities make it a versatile candidate for therapeutic applications across multiple disease domains. As research continues to uncover new insights into its pharmacological properties,20(S)-Ginsenoside Rh2 is poised to play an increasingly important role in modern medicine.

• 52286-58-5(Ginsenoside Rf)
• 38243-03-7((20R)-Ginsenoside Rg3)
• 22427-39-0(Ginsenoside RG1)
• 41753-43-9(Ginsenoside Rb1)
• 52286-59-6(Ginsenoside Re)
• 52705-93-8(ginsenoside rd)
• 53963-43-2(Ginsenoside F1)
• 14197-60-5(20(S)-Ginsenoside Rg3)
• 52286-74-5(Ginsenoside Rg2)
• 11021-13-9(Ginsenoside Rb2)